Agrenvec is a European biotech specialized in plant production of mammalian recombinant proteins and antibodies for the R&D market. Was created as a start-up company in 2002 with the in-licensing of several patents from the INIA (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria).
We are focused on the development, manufacture and marketing, of products and services for the R&D and Industrial markets. Our Company owns a patented technology platform allowing us a high-throughput production of Animal free fully active recombinant proteins with complex 3D structure and with a purity of 97%.
Supported by a multi-disciplinary group of experts with an extensive professional career, Agrenvec is one of the few companies in the world capable of using the viral vectors technology to turn plants into bio-factories. It counts with a stable work team of fourteen highly qualified professionals, 30% of our personnel have a PhD and 60% a university degree. Our manager team has a long experience in the pharmaceutical and biotechnological industry.